Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Effect of simultaneous administration of Avemar and cytostatic drugs on viability of cell cultures, growth of experimental tumors, and survival tumor-bearing mice.

Effect of Avemar, In mice, Avemar, Case Study, Cancer Research No Comments

 

Avemar (Biromedicina Co., Budapest, Hungary), a wheat germ preparation with immunomodulant and antimetastatic activity, was applied simultaneously with cytostatic drugs of different modes of action, in vitro and in vivo, in order to find out whether this simultaneous administration exerts an antagonistic or a synergistic effect on the viability of cell cultures, tumor growth, and survival of animals, inoculated with a transplantable mouse tumor (3LL-HH). In vitro, Avemar did not influence the effect on the viability of MCF-7, HepG2, or Vero cells, exerted by Dacarbazine, 5-fluorouracyl, or Adriblastina. In vivo, Avemar, combined with Endoxan, Navelbine, and doxorubicin, did not prevent the tumor growth inhibitory effect of the cytostatic drugs. The combination of Avemar with the cytostatic drugs did not increase the toxicity of the cytostatic compounds, and did not exert any toxic effect. Avemar may be administered together with cytostatic drugs, without the risk of increasing toxicity or decreasing antiproliferative activity.

Download Research Data :

New Cancer Research
Read the rest…

Inhibition of metastases in mice

In mice, Avemar, Cancer Research, Product No Comments

Experiments were carried out in inbred G57B1/6 mice of 8-10 weeks of age weighing 20-22g on the following cancer cell-lines: meta-stasizing Lewis lung carcinoma (3LL-HH) injected into the spleen, B-16 mouse melanoma injected into muscle tissue and HCR-25 human colon carcinoma xenograft injected into the spleen. The administration of Avemar began 24 hours after the tumor cells were implanted.

Results: metastasis formation in liver decreased by 71% (significant) following treatment with Avemar for the 3LL-HH tumor cells. For HCR-25 human colon carcinoma, 50 days of treatment with Avemar resulted in a significant (50%) decrease in both the number and size of liver metastases as well as the size of the primary tumor injected into spleen. The number of metastases in B-16 melanoma decreased by 85% (significant) after 21 days of treatment [1]. Control groups were used for all cancer types.

Conclusions: Avemar’s tumour-inhibiting effect can be taken as a fact.
Download Research Data :